BLUE dividend history

New headquarters designed to reflect modern ways of working and deliver significant cost savings bluebird bio, Inc. (NASDAQ:BLUE) announced today that it has signed a long-term lease with Federal Realty (Federal) to establish a biotech hub at Assembly Row. The 61,000 square foot facility to be located at 455 Grand Union Blvd. in Somerville is designed to meet the changing needs of bluebird bio's business, including its dedicated focus on gene therapies for severe genetic diseases following the recent spinoff of its oncology portfolio. The company expects to move approximately 425 employees to its new headquarters in spring of 2022. The workspace is designed to enable a distributed work m

bluebird bio, Inc. (NASDAQ:BLUE) today announced that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies. Each bluebird bio stockholder of record as of the close of business on October 19, 2021 will receive, on the distribution date, one share of 2seventy common stock for every three shares of bluebird common stock held. The share dividend is expected to be distributed to bluebird stockholders on or about November 4, 2021. Following the separation, bluebird stockholders will a

Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY; Revenue Increase of 8% Excluding COVID-19 Related Buying Patterns from Prior Year Period Posts First Quarter Earnings Per Share of $0.89 and Non-GAAP EPS of $1.74 Strengthens Leadership in Immuno-Oncology with Multiple Regulatory and Data Milestones for Opdivo and Yervoy Delivers Positive Results from Phase 2/3 RELATIVITY-047 Trial Evaluating Relatlimab and Opdivo for Previously Untreated Metastatic or Unresectable Melanoma Advances Cell Therapy Franchise with FDA Approvals for Abecma and Breyanzi Presents Positive Results from POETYK-1 and POETYK-PSO-2 Phase 3 Trial Evaluating Deucravacitinib (TYK2 inhibito

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2020, which reflect robust sales, strong operating performance and advancement of the company’s product pipeline. “In our first full year as a new company we delivered solid operational and financial results, and laid a strong foundation for the future,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “I am grateful to our team whose resilience and continued focus enabled us to grow our inline business, launch promising new drugs and significantly advance our pipeline while keeping our colleagues safe and maintaining th